Shenyang Sinqi Pharmaceutical Co., Ltd (SHE: 300573), a pharmaceutical company based in China, has received clinical trial approval from the National Medical Products Administration (NMPA) for its therapeutic biologic, SQ-22031 eye drops. This Category 1 therapeutic biologic is intended for the treatment of dry eye syndrome and neurotrophic keratitis, with the latter being a condition recognized in China’s second batch of rare diseases. Comprehensive studies on SQ-22031, encompassing pharmacology, non-clinical pharmacology, and toxicology, have yielded results that underscore the product’s favorable safety profile and potential clinical development value.- Flcube.com
Clinical trial approval / initiation Ophthalmology Rare / orphan disease drugs SHE: 300573 Sinqi Pharmaceutical
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
